2025 Preview

2024 has been a bit of a mixed bag for the pharma market.

Hopes for a strong recovery haven’t quite materialised, with a patchy year for M&A falling short of expectations from late 2023.

Meanwhile, the IPO window remains barely ajar, and complexities like the BIOSECURE Act and global elections have added to the uncertainty.

Share:

Watch now








About this webinar

So, what does 2025 have in store for biopharma and biotech?

In this webinar, we take a closer look at the short-term horizon to explore the companies, drugs and therapy areas we expect to dominate in 2025.

Plus, we consider what this could mean for investor sentiment and the sector’s longer-term recovery.

Key discussion points:

  • Are GLP-1s still dominating the top 10? What does that mean for the leading companies in 2025?
  • Where are the most valuable pipeline products emerging?
  • Which therapy areas and new drugs are likely to drive growth?
  • Are we finally set for a return to dealmaking?
  • And what impact could the new Trump administration have on deals and the wider pharma outlook in 2025?

Speakers

Evaluate-Author-Daniel-Chancellor

Daniel Chancellor

VP, Norstella Thought Leadership
Evaluate-Author-Mark-Lansdell

Mark Lansdell

Asset and Portfolio Strategy Lead, Evaluate
alexandra-shimmings

Alexandra Shimmings

Executive Editor R&D & Commercial, Scrip

Explore all webinars